In COMMANDER-HF, conducted in patients with recently decompensated heart failure treated with rivaroxaban, no significant impact on the primary outcome was demonstrated. Results are discussed with John Cleland (National Heart and Lung Institute, Imperial College London) at the ESC Congress 2018.
The COMMANDER-HF trial
Dai congressiIntervisteCARDIOINFO@ESC2018
Scelti dall'editore
- Practical implications of the COMPASS trial results
John W. Eikelboom Associate Professor - Department of Medicine McMaster University, Hamilton
- MANAGE trial and perioperative MI
Philip J. Devereaux Dpts of Health Research Methods, Evidence and Impact and Medicine McMaster University,…